Description
Key facts
Cell type:Raji,
Species or organism:Human,
Tissue:Lymphatic,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9; X = 2 bp deletion; Frameshift: 100%,
Disease:Lymphoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-MS4A1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD20 also known as MS4A1 or L26 is a membrane-spanning 4-domains subfamily A member 1 protein. It is a non-glycosylated phosphoprotein with a molecular mass of approximately 33-37 kDa. Expressed extensively on the surface of B-cells CD20 plays an important role in B-cell activation and regulation. While CD20 is absent on early pro-B cells and plasma cells its presence increases as B-cells mature. Anti-CD20 antibodies such as 2H7 are commonly used in research and treatment to deplete B-cells due to the target's consistent expression in most stages of B-cell development.
Biological function summary
CD20 contributes significantly to calcium ion transport which is essential for the activation process of B-cells. Although CD20 does not belong to a larger protein complex its role centers around forming a calcium channel that allows a sustained influx of calcium into the B-cells. This influx is important for the signaling pathways that govern B-cell activation proliferation and differentiation impacting the immune response efficacy.
Pathways
CD20 is closely involved in the B-cell receptor (BCR) signaling pathway and the Fc gamma R-mediated phagocytosis pathway. These pathways play vital roles in adaptive immunity and immune response modulation. CD20's interaction with proteins like PI3K during BCR signaling enhances receptor-mediated cellular signals subsequently influencing downstream effectors involved in cell growth and survival of B-cells.
CD20 is strongly linked to certain blood cancers and autoimmune diseases including non-Hodgkin's lymphoma and rheumatoid arthritis. These conditions often exploit aberrant B-cell activity or count. CD20's expression on malignant B-cells in non-Hodgkin's lymphoma makes it an effective target for monoclonal antibody therapies such as rituximab an anti-CD20 antibody. Additionally CD20-targeted therapies can help deplete pathogenic B-cells in rheumatoid arthritis highlighting the protein's relevance in disease treatment.
